AAV gene delivery to the spinal cord: serotypes, methods, candidate diseases, and clinical trials
N Hardcastle, NM Boulis, T Federici - Expert opinion on biological …, 2018 - Taylor & Francis
N Hardcastle, NM Boulis, T Federici
Expert opinion on biological therapy, 2018•Taylor & FrancisIntroduction: Adeno-associated viral (AAV) vector-mediated gene delivery to the spinal cord
has finally entered the pathway towards regulatory approval. Phase 1 clinical trials using
AAV gene therapy for pediatric disorders–spinal muscular atrophy (SMA) and giant axonal
neuropathy (GAN)–are now underway. Areas covered: This review addresses the latest
progress in the field of AAV gene delivery to the spinal cord, particularly focusing on the
most prominent AAV serotypes and delivery methodologies to the spinal cord. Candidate …
has finally entered the pathway towards regulatory approval. Phase 1 clinical trials using
AAV gene therapy for pediatric disorders–spinal muscular atrophy (SMA) and giant axonal
neuropathy (GAN)–are now underway. Areas covered: This review addresses the latest
progress in the field of AAV gene delivery to the spinal cord, particularly focusing on the
most prominent AAV serotypes and delivery methodologies to the spinal cord. Candidate …
Abstract
Introduction: Adeno-associated viral (AAV) vector-mediated gene delivery to the spinal cord has finally entered the pathway towards regulatory approval. Phase 1 clinical trials using AAV gene therapy for pediatric disorders – spinal muscular atrophy (SMA) and giant axonal neuropathy (GAN) – are now underway.
Areas covered: This review addresses the latest progress in the field of AAV gene delivery to the spinal cord, particularly focusing on the most prominent AAV serotypes and delivery methodologies to the spinal cord. Candidate diseases and scaling up experiments in large animals are also discussed.
Expert opinion: Intravenous (IV) and intrathecal (IT) deliveries seem to undoubtedly be the preferred routes of administration for diffuse spinal cord delivery of therapeutic AAV vectors that can cross the blood-brain barrier (BBB) and correct inherited genetic disorders. Conversely, intraparenchymal delivery is still an undervalued but very viable approach for segmental therapy in afflictions such as ALS or Pompe Disease as a means to prevent respiratory dysfunction.
Taylor & Francis Online